CD158k Is a Reliable Marker for Diagnosis of Sézary Syndrome and Reveals an Unprecedented Heterogeneity of Circulating Malignant Cells-Reference-Cited by-同舟云学术

CD158k Is a Reliable Marker for Diagnosis of Sézary Syndrome and Reveals an Unprecedented Heterogeneity of Circulating Malignant Cells

Published:2015-01 Issue:1 Volume:135 Page:247-257
ISSN:0022-202X
Container-title:Journal of Investigative Dermatology
language:en
Short-container-title:Journal of Investigative Dermatology

Author:

Moins-Teisserenc Hélène,Daubord Magali,Clave Emmanuel,Douay Corinne,Félix Joana,Marie-Cardine Anne,Ram-Wolff Caroline,Maki Guitta,Beldjord Kheira,Homyrda Laurence,Michel Laurence,Bensussan Armand,Toubert Antoine,Bagot Martine

Publisher

Elsevier BV

Subject

Cell Biology,Dermatology,Molecular Biology,Biochemistry

Reference39 articles.

1. Epidermotropic T cell lymphomas as models for tumor progression;Bagot;Med Sci (Paris),2006

2. CD4(+) cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor;Bagot;Blood,2001

3. CD158k/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sezary syndrome by flow cytometry;Bahler;Cytometry B Clin Cytom,2008

4. The relevance of the CD4+ CD26- subset in the identification of circulating Sezary cells;Bernengo;Br J Dermatol,2001

5. Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in sezary syndrome patients;Bouaziz;J Invest Dermatol,2005

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of Sézary cell marker expression and cell death behaviour upon in vitro treatment by flow cytometry in Sézary syndrome patients;Experimental Dermatology;2024-09

2. Pathophysiology of cutaneous T-cell lymphomas: Perspective from a French referral centre;Immunology Letters;2024-08

3. Delving into the Metabolism of Sézary Cells: A Brief Review;Genes;2024-05-17

4. Unleashed monocytic engagement in Sézary syndrome during the combination of anti-CCR4 antibody with type I interferon;Blood Advances;2024-05-17

5. Syndrome de Sézary;Hématologie;2024-01-01